Chapter review

Must know

• ADHD Subtype Clusters — Part 1: InattentionDiagnostic criteria require at least 6 inattention symptoms for children up to age 16, or at least 5 symptoms for individuals age 17 and older, persisting for at least 6 months.

  • Diagnostic criteria require at least 6 inattention symptoms for children up to age 16, or at least 5 symptoms for individuals age 17 and older, persisting for at least 6 months.
  • Several inattentive or hyperactive-impulsive symptoms must be present prior to 12 years of age.
  • Clear impairment from symptoms must be present across at least 2 distinct settings, such as at home and in the classroom.
  • Elementary school prevalence is 7% to 8% in children and 2.5% in adults, with a male-to-female ratio of 2 to 1 in children and 1.6 to 1 in adults.
  • Heritability for ADHD is approximately 75%, carrying a 2-to-8-fold increased risk among siblings of affected children.
  • First-line treatment for school-age children combines stimulant pharmacotherapy using methylphenidate or amphetamine preparations with behavioral interventions.
• Clinical Framework and Key SignpostsStimulants, including methylphenidate preparations and amphetamine salts, represent first-line pharmacotherapy for ADHD in school-age children, adolescents, and adults. They should be combined with behavioral strategies and parent support resources such as CHADD.

  • Stimulants, including methylphenidate preparations and amphetamine salts, represent first-line pharmacotherapy for ADHD in school-age children, adolescents, and adults. They should be combined with behavioral strategies and parent support resources such as CHADD.
  • Do not assume a child with a well-controlled seizure disorder cannot receive stimulants. Stimulants remain safe and effective when seizures are stabilized on an anticonvulsant. Avoid bupropion in patients with epilepsy because bupropion significantly lowers the seizure threshold.

  Board trap. Do not assume a child with a well-controlled seizure disorder cannot receive stimulants. Stimulants remain safe and effective when seizures are stabilized on an anticonvulsant. Avoid bupropion in patients with epilepsy because bupropion significantly lowers the seizure threshold.

  Safety. Stimulants increase presynaptic dopamine and norepinephrine, requiring baseline and quarterly monitoring of height, weight, blood pressure, and pulse. Avoid or use with extreme caution in structural cardiac abnormalities, uncontrolled hypertension, active substance use disorders,

• ADHD Subtype Clusters: Inattention Domain and Diagnostic Architecture1. Failing to give close attention to details or making careless mistakes in schoolwork, work, or other activities.

  • 1. Failing to give close attention to details or making careless mistakes in schoolwork, work, or other activities.
  • 2. Difficulty sustaining attention in tasks, lengthy lectures, or play activities.
  • 3. Appearing not to listen when spoken to directly, as if the mind is elsewhere without any obvious distraction.
  • 4. Failing to follow through on instructions and failing to finish schoolwork, chores, or workplace duties due to starting tasks but quickly losing focus.
  • 5. Difficulty organizing tasks and activities, manifested by messy backpacks, disorganized lockers, poor time management, and failing to turn in completed homework assignments.
  • 6. Avoiding, disliking, or being reluctant to engage in tasks that require sustained mental effort, such as school projects or lengthy reports.
• ADHD Subtype Clusters — Part 2: Hyperactivity and ImpulsivityADHD hyperactive-impulsive subtype requires 6 or more out of 9 criteria for children under 17 years, and 5 or more out of 9 criteria for individuals 17 years or older.

  • ADHD hyperactive-impulsive subtype requires 6 or more out of 9 criteria for children under 17 years, and 5 or more out of 9 criteria for individuals 17 years or older.
  • Symptoms must persist for at least 6 months, have an onset prior to age 12, and cause demonstrable impairment across at least 2 distinct settings.
  • Elementary school prevalence is 7 to 8 percent in children and 2.5 percent in adults, with a 2 to 1 male-to-female ratio in youth and a high heritability rate of 75 percent.
  • First-line pharmacotherapy for school-aged youth is stimulant medication (methylphenidate or amphetamine salts), whereas behavioral therapy is first-line for children under 5 years.
  • Baseline cardiac risk evaluation, blood pressure, pulse, height, and weight must be monitored at initiation and quarterly during stimulant treatment.
  • Bupropion is strictly contraindicated in patients with seizure disorders due to lowering the seizure threshold, whereas methylphenidate can be safely restarted if seizures are well controlled on anticonvulsants.

  Board trap. Bupropion is strictly contraindicated in patients with seizure disorders due to lowering the seizure threshold, whereas methylphenidate can be safely restarted if seizures are well controlled on anticonvulsants.

  Safety. Baseline cardiac risk evaluation, blood pressure, pulse, height, and weight must be monitored at initiation and quarterly during stimulant treatment.

• Diagnostic ArchitectureCore threshold: 6 or more symptoms of hyperactivity-impulsivity for individuals up to 16 years of age. 5 or more symptoms required for individuals 17 years of age and older.

  • Core threshold: 6 or more symptoms of hyperactivity-impulsivity for individuals up to 16 years of age. 5 or more symptoms required for individuals 17 years of age and older.
  • Duration requirement: Symptoms must persist for at least 6 consecutive months to a degree that is maladaptive and inconsistent with developmental level.
  • Age of onset gate: Several hyperactive-impulsive or inattentive symptoms must be present prior to age 12 years.
  • Setting gate: Symptoms or impairment must be present in 2 or more settings, such as home, school, sports, or work.
  • Functional interference: Clear evidence of significant interference with social, academic, or occupational functioning.
• FIDGETY MnemonicF: Fidgets with hands or feet, or squirms in seat.

  • F: Fidgets with hands or feet, or squirms in seat.
  • I: In seat fails to remain when remaining seated is expected in classroom or work settings.
  • D: Driven by a motor, acting as if on the go, or running/climbing excessively in inappropriate situations.
  • G: Gabs excessively, demonstrating continuous over-talkativeness.
  • E: Early answer blurted out before a question has been fully completed.
  • T: Turns waiting difficulty, struggling to wait turn in lines or group games.
• Developmental EvolutionYoung children manifest hyperactivity as overt gross motor behaviors like climbing on furniture, running constantly, and failing to engage in quiet play.

  • Young children manifest hyperactivity as overt gross motor behaviors like climbing on furniture, running constantly, and failing to engage in quiet play.
  • Adolescents and adults display less gross motor running but experience a subjective internal feeling of restlessness, excessive talking, and impulsive decision-making.
• First-lineFirst-line treatment for children aged 6 and older with ADHD is stimulant pharmacotherapy (methylphenidate or dextroamphetamine).

  • First-line treatment for children aged 6 and older with ADHD is stimulant pharmacotherapy (methylphenidate or dextroamphetamine).
  • First-line intervention for preschool children under age 5 is evidence-based parent training in behavior management before initiating medications.
  • First-line strategy when motor tics develop during stimulant therapy is switching to a non-stimulant like atomoxetine.
• Board trapDo not confuse ADHD hyperactivity with bipolar mania. Mania is episodic and cyclic, whereas ADHD is a chronic baseline state. Both share distractibility and excessive talking, but grandiosity and decreased need for sleep point to mania.

  • Do not confuse ADHD hyperactivity with bipolar mania. Mania is episodic and cyclic, whereas ADHD is a chronic baseline state. Both share distractibility and excessive talking, but grandiosity and decreased need for sleep point to mania.
  • Do not withhold stimulants in patients with well-controlled seizure disorders. Methylphenidate does not lower seizure threshold when seizures are stabilized on anticonvulsants, whereas bupropion is strictly contraindicated.
  • Expected stimulant side effects include insomnia, reduced appetite, weight loss, and transient headache. Hypersomnia is not a stimulant side effect.
• Safety alertMonitor blood pressure, heart rate, height, and weight at baseline and quarterly during stimulant therapy to evaluate for cardiovascular changes and growth suppression.

  • Monitor blood pressure, heart rate, height, and weight at baseline and quarterly during stimulant therapy to evaluate for cardiovascular changes and growth suppression.
  • Exercise caution when prescribing stimulants in patients with hypertension, structural cardiac abnormalities, active motor tics, severe anxiety/agitation, or a prior history of substance use disorder.
• Hyperactivity in ADHD vs Bipolar I ManiaThink: ADHD is chronic and continuous from childhood; mania is episodic with distinct mood changes.

  • Think: ADHD is chronic and continuous from childhood; mania is episodic with distinct mood changes.
  • Priority: Distinguish baseline restlessness from acute manic grandiosity and decreased need for sleep.
  • Boards are testing: ADHD symptoms do not wax and wane in discrete manic cycles.
• ADHD Hyperactive Subtype vs Anxiety DisordersThink: Anxiety-driven motor restlessness is linked to internal worry; ADHD motor restlessness is driven by executive dysfunction.

  • Think: Anxiety-driven motor restlessness is linked to internal worry; ADHD motor restlessness is driven by executive dysfunction.
  • Priority: Assess whether restlessness occurs only during anxious triggers or across all daily settings continuously.
  • Boards are testing: Anxiety and ADHD co-occur in up to 70 percent of cases, but primary anxiety features excessive apprehension.
• ADHD Impulsivity vs Oppositional Defiant DisorderThink: ADHD impulsivity is unintended impatience or blurted responses; Oppositional Defiant Disorder is deliberate defiance, spitefulness, and arguing with authority.

  • Think: ADHD impulsivity is unintended impatience or blurted responses; Oppositional Defiant Disorder is deliberate defiance, spitefulness, and arguing with authority.
  • Priority: Oppositional Defiant Disorder is treated with family behavioral therapy; ADHD is treated with stimulants.
  • Boards are testing: Academic failure is not a diagnostic criterion for Oppositional Defiant Disorder or conduct disorder.
• Pharmacological Management of ASD SymptomsAutism Spectrum Disorder requires persistent deficits across two core domains: social communication/interaction and restricted, repetitive patterns of behavior or interests.

  • Autism Spectrum Disorder requires persistent deficits across two core domains: social communication/interaction and restricted, repetitive patterns of behavior or interests.
  • Pharmacotherapy does not cure or treat core social communication deficits in Autism Spectrum Disorder.
  • Risperidone and aripiprazole are the only two atypical antipsychotics with FDA approval for treating irritability, aggression, and explosive tantrums associated with Autism Spectrum Disorder in pediatric patients.
  • Applied Behavioral Analysis (ABA) therapy is the gold-standard, first-line non-pharmacological behavioral intervention, recommended for up to 20 hours per week starting early in development.
  • The M-CHAT-R (Modified Checklist for Autism in Toddlers, Revised) is the standard screening tool used between 16 and 30 months; a score of 8 or higher indicates high risk for Autism Spectrum Disorder.
  • Initial clinical presentations often involve parents suspecting a hearing impairment due to the child's lack of response to their name or poor social responsiveness.
• Must-Know Concepts for BoardsApplied Behavioral Analysis (ABA) therapy is the primary first-line non-pharmacological treatment of choice for managing behavior in Autism Spectrum Disorder.

  • Applied Behavioral Analysis (ABA) therapy is the primary first-line non-pharmacological treatment of choice for managing behavior in Autism Spectrum Disorder.
  • Risperidone and aripiprazole are first-line FDA-approved psychotropic choices when severe irritability, physical aggression, temper tantrums, or self-injurious behaviors impair functioning or safety.
  • Do not prescribe psychotropic medications with the expectation of correcting core social deficits, speech delays, or lack of eye contact. Medications target secondary behavioral symptoms like severe irritability, severe hyperactivity, or aggression.
  • When parents report a toddler fails to respond to spoken commands or verbal cues, do not assume a primary hearing deficit without first screening for Autism Spectrum Disorder using the M-CHAT-R tool.

  Board trap. Do not prescribe psychotropic medications with the expectation of correcting core social deficits, speech delays, or lack of eye contact. Medications target secondary behavioral symptoms like severe irritability, severe hyperactivity, or aggression.

  Safety. Baseline metabolic screening is mandatory before starting risperidone or aripiprazole. Measure weight, height, body mass index, blood pressure, fasting blood glucose, and fasting lipid panel at baseline and monitor quarterly due to high risks of rapid weight gain, metabolic syndr

• Pharmacological Management PrinciplesFor severe irritability, physical aggression, explosive temper tantrums, and self-injurious behavior: Initiate risperidone or aripiprazole. Start at the lowest effective dose and titrate gradually.

  • For severe irritability, physical aggression, explosive temper tantrums, and self-injurious behavior: Initiate risperidone or aripiprazole. Start at the lowest effective dose and titrate gradually.
  • For co-occurring inattention or hyperactivity: Evaluate for comorbid ADHD. Stimulants like methylphenidate or non-stimulants like atomoxetine and alpha-2 adrenergics like guanfacine may be used, though children with ASD display higher sensitivity to side effects.
  • Practice cautious prescribing: Avoid polypharmacy and re-evaluate the ongoing need for medication periodically.
• Disruptive Behavior Disorders: ODD vs. Conduct DisorderOppositional Defiant Disorder (ODD) requires a persistent pattern of angry or irritable mood, argumentative or defiant behavior, or vindictiveness lasting at least 6 months, exhibited with at least one individual who is not a sibling.

  • Oppositional Defiant Disorder (ODD) requires a persistent pattern of angry or irritable mood, argumentative or defiant behavior, or vindictiveness lasting at least 6 months, exhibited with at least one individual who is not a sibling.
  • Diagnostic age gates for ODD require symptoms on most days for at least 6 months in children under 5 years of age, and at least once per week for at least 6 months in individuals 5 years of age or older.
  • Conduct Disorder (CD) requires a repetitive pattern violating the basic rights of others or major societal rules, evidenced by at least 3 criteria in the past 12 months, with at least 1 criterion present in the past 6 months.
  • Conduct Disorder features four major symptom domains: aggression to people and animals, destruction of property, deceitfulness or theft, and serious violations of rules.
  • Age of onset divides Conduct Disorder into Childhood-Onset (at least 1 criterion present before age 10, carrying a worse prognosis) and Adolescent-Onset (no criteria before age 10).
  • An individual must be under 18 years of age for a diagnosis of Conduct Disorder. If the individual is 18 years or older, criteria for Antisocial Personality Disorder must be evaluated instead.
• Oppositional Defiant Disorder (ODD)What it is: A pediatric behavioral disorder defined by an enduring pattern of emotional dysregulation, verbal defiance, hostility, and spitefulness toward authority figures.

  • What it is: A pediatric behavioral disorder defined by an enduring pattern of emotional dysregulation, verbal defiance, hostility, and spitefulness toward authority figures.
  • Why boards care: The exam tests your ability to distinguish verbal hostility and boundary-testing from the physical aggression, property damage, and illegal acts seen in Conduct Disorder.
  • Typical board clue: A 7-year-old child who argues with teachers, loses his temper, blames classmates for his own mistakes, and deliberately annoys peers, but shows no physical cruelty or property destruction.
  • First-line approach: Family behavioral therapy and parent management training.
  • When the answer changes: If the child begins physically harming animals, setting fires, stealing, or running away overnight, the diagnosis escalates to Conduct Disorder.
  • Evaluate for comorbid ADHD, major depressive disorder, and anxiety disorders, which occur in up to 70% of affected youth.

  Safety. Evaluate for comorbid ADHD, major depressive disorder, and anxiety disorders, which occur in up to 70% of affected youth.

• Conduct Disorder (CD)What it is: A severe behavioral disorder characterized by a repetitive pattern of violating basic human rights and major age-appropriate societal rules or laws.

  • What it is: A severe behavioral disorder characterized by a repetitive pattern of violating basic human rights and major age-appropriate societal rules or laws.
  • Why boards care: Tested heavily on safety priorities, age of onset specifiers, legal violations, and differential diagnosis with adult Antisocial Personality Disorder.
  • Typical board clue: A 14-year-old adolescent boy with a history of physical fights, animal cruelty, fire-setting, shoplifting, and running away overnight.
  • First-line approach: Multi-systemic therapy, family behavioral therapy, and social skills training. Out-of-home residential placement may be required for severe safety violations.
  • When the answer changes: If the patient reaches 18 years of age and demonstrates a pattern of disregard for the rights of others since age 15, the diagnosis changes to Antisocial Personality Disorder.
  • Conduct Disorder carries high risks of physical violence, fire-setting, weapon use, cruelty to animals, and co-occurring substance use disorder. Immediate risk assessment for harm to others is essential.

  Safety. Conduct Disorder carries high risks of physical violence, fire-setting, weapon use, cruelty to animals, and co-occurring substance use disorder. Immediate risk assessment for harm to others is essential.

• Oppositional Defiant Disorder vs. Conduct DisorderDo not confuse: ODD centers on verbal defiance, hostility, and emotional dysregulation without major property damage or physical aggression. Conduct Disorder centers on overt property destruction, physical harm, theft, and societal rule violations.

  • Do not confuse: ODD centers on verbal defiance, hostility, and emotional dysregulation without major property damage or physical aggression. Conduct Disorder centers on overt property destruction, physical harm, theft, and societal rule violations.
  • Think ODD when: The child loses temper, argues with adults, defies rules, blames others for mistakes, and deliberately annoys people, but does not commit illegal acts or physical harm.
  • Think Conduct Disorder when: The youth steals, sets fires, uses weapons, displays physical cruelty to animals or people, or stays out overnight before age 13.
  • Priority difference: ODD is managed in outpatient settings with family behavioral interventions. Conduct Disorder presents immediate safety and legal risks requiring comprehensive multi-systemic safety planning and potential residential care.
  • What boards are really testing: Recognizing the boundary between emotional/verbal defiance (ODD) and physical aggression/lawbreaking (Conduct Disorder), as well as understanding that academic failure is an associated outcome, not a diagnostic criterion.
  • Classic distractor: Choosing medication (like an SSRI or stimulant) as the primary treatment for ODD or Conduct Disorder, or selecting poor academic performance as a required diagnostic criterion.
• Key Exam Signposts and Board PearlsPsychotherapy and behavioral interventions are always first-line. Family behavioral therapy for ODD; multi-systemic therapy and social skills training for Conduct Disorder.

  • Psychotherapy and behavioral interventions are always first-line. Family behavioral therapy for ODD; multi-systemic therapy and social skills training for Conduct Disorder.
  • Believing that poor academic performance or failing grades is a diagnostic criterion for Conduct Disorder or ODD. Academic failure is a common consequence of these behaviors, not a diagnostic criterion.
  • Prescribing psychotropic medications as the primary treatment for ODD or Conduct Disorder. Medications are only indicated to treat comorbid conditions like ADHD or to manage severe, refractory physical aggression with atypical antipsychotics like risperidone.
  • Conduct Disorder behaviors such as arson, weapon use, physical cruelty to animals or humans, and running away overnight represent immediate safety hazards that require protective intervention.

  Board trap. Believing that poor academic performance or failing grades is a diagnostic criterion for Conduct Disorder or ODD. Academic failure is a common consequence of these behaviors, not a diagnostic criterion.

  Safety. Conduct Disorder behaviors such as arson, weapon use, physical cruelty to animals or humans, and running away overnight represent immediate safety hazards that require protective intervention.

• Table 15-17: Disruptive and Impulse-Control TreatmentsOppositional Defiant Disorder (ODD) requires an 8-month or at least 6-month pattern of irritable mood, argumentative behavior, defensiveness, and vindictiveness toward authority figures.

  • Oppositional Defiant Disorder (ODD) requires an 8-month or at least 6-month pattern of irritable mood, argumentative behavior, defensiveness, and vindictiveness toward authority figures.
  • First-line treatment for ODD is family behavioral therapy; psychotropic medications like SSRIs are not indicated as primary treatment.
  • Conduct Disorder (CD) requires a persistent pattern of behavior violating the basic rights of others or major societal rules across four core categories: aggression to people/animals, destruction of property, deceitfulness or theft, and serious violations of rules.
  • Poor academic performance is a functional consequence of disruptive behavior, NOT a core diagnostic criterion for Conduct Disorder or ODD.
  • Treatment for Conduct Disorder combines social skills training and family education; severe cases may require out-of-home placement in a group home or intensive residential facility.
  • Dietary modifications, such as limiting refined carbohydrates, have no evidence-based role in treating disruptive behavior disorders.

  Board trap. Poor academic performance is a functional consequence of disruptive behavior, NOT a core diagnostic criterion for Conduct Disorder or ODD.

• Core Clinical Teaching: Disruptive and Impulse-Control DisordersFirst-line intervention for ODD is family behavioral therapy. Prescribing psychotropic medications such as SSRIs is inappropriate as an initial strategy, and advising parents that the child will outgrow the behavior delays necessary evidence-based care.

  • First-line intervention for ODD is family behavioral therapy. Prescribing psychotropic medications such as SSRIs is inappropriate as an initial strategy, and advising parents that the child will outgrow the behavior delays necessary evidence-based care.
  • 1. Aggression toward people and animals
  • 2. Destruction of property
  • 3. Deceitfulness or theft
  • 4. Serious rule violations, such as truancy or running away

  Board trap. Exam stems frequently mention that a child with ODD or Conduct Disorder is failing in school or performing poorly academically. Test writers use this to distract candidates into selecting learning disability workups or academic accommodations instead of recognizing the primary di

  Safety. Conduct Disorder involves dangerous behaviors like physical cruelty, weapon use, arson, and property destruction. Management requires social skills training and structured family education. When safety cannot be maintained in the home environment, clinicians must coordinate out-o

• Standardized Assessment for Youth MoodMajor Depressive Disorder in youth frequently manifests as irritable mood or feeling "mad at the world" rather than classic sadness, along with failure to make expected developmental weight gains, initial insomnia, or after-school fatigue.

  • Major Depressive Disorder in youth frequently manifests as irritable mood or feeling "mad at the world" rather than classic sadness, along with failure to make expected developmental weight gains, initial insomnia, or after-school fatigue.
  • Only two antidepressants are FDA approved for pediatric depression: fluoxetine for patients aged 8 years and older, and escitalopram for patients aged 12 years and older.
  • All antidepressants carry an FDA Black Box warning for an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults up to age 24.
  • Disruptive Mood Dysregulation Disorder requires chronic, severe persistent irritability with temper outbursts occurring at least 3 times per week for over 12 months, with symptom onset before age 10 years and manifestation across at least 2 settings.
  • Youth diagnosed with Major Depressive Disorder carry a 20% to 40% risk of developing bipolar disorder, with higher risk linked to prepubertal onset, a multigenerational family history of mood disorders, or psychotic features.
  • Standardized mood and psychosocial screening tools include the PHQ-A (modified PHQ-9 for adolescents), the Pediatric Symptom Checklist (PSC-17 or PSC-35), the Vanderbilt screening tool, and the HEADS mnemonic.
• Standardized Screening Tools for Pediatric Mood and Behavioral AssessmentPHQ-A: Modified Patient Health Questionnaire for adolescents used to screen for and monitor depressive symptom severity.

  • PHQ-A: Modified Patient Health Questionnaire for adolescents used to screen for and monitor depressive symptom severity.
  • Pediatric Symptom Checklist: Available as PSC-17 or PSC-35, used as a broad pre-visit screening tool sent to parents and teachers prior to the initial consultation to evaluate emotional and behavioral domains.
  • Vanderbilt Screening Tool: Completed by both parents and teachers to assess symptoms across domains of inattention, disruption, behavior, anxiety, depression, and academic performance.
  • HEADS Mnemonic: A structured psychosocial assessment framework for adolescents covering Home, Education and future plans, Activities, Drugs and alcohol use, Sex and sexuality, and Suicidality or mental health concerns.
• Diagnostic Criteria and Clinical FeaturesMajor Depressive Disorder:

  • Major Depressive Disorder:
  • Presentation in youth often features marked irritability, social withdrawal, drop in grades, somatic complaints, and failure to make expected developmental weight gains.
  • Up to 20% to 40% of pediatric patients with Major Depressive Disorder eventually develop bipolar disorder.
  • Disruptive Mood Dysregulation Disorder:
  • Diagnostic threshold: Severe, recurrent temper outbursts out of proportion to the situation, occurring 3 or more times per week for at least 12 months without a symptom-free period exceeding 3 consecutive months.
  • Age gates: Onset of symptoms must occur before age 10 years, and the diagnosis should not be made for the first time before age 6 years or after age 18 years.
• Treatment Principles and Safety StandardsPsychotherapy such as cognitive behavioral therapy or interpersonal therapy is a primary first-line intervention. When pharmacotherapy is indicated, fluoxetine (approved for age 8 and older) or escitalopram (approved for age 12 and older) is the first-line choice.

  • Psychotherapy such as cognitive behavioral therapy or interpersonal therapy is a primary first-line intervention. When pharmacotherapy is indicated, fluoxetine (approved for age 8 and older) or escitalopram (approved for age 12 and older) is the first-line choice.
  • Monitor youth closely for suicidal ideation, behavioral activation, or agitation during the initial 1 to 2 months of starting antidepressant therapy due to the FDA Black Box warning for suicidality in individuals under age 25.
  • Do not select tricyclic antidepressants for pediatric depression. They are ineffective in children and carry a high risk of lethal cardiac arrhythmias in overdose.

  Board trap. Do not select tricyclic antidepressants for pediatric depression. They are ineffective in children and carry a high risk of lethal cardiac arrhythmias in overdose.

  Safety. Monitor youth closely for suicidal ideation, behavioral activation, or agitation during the initial 1 to 2 months of starting antidepressant therapy due to the FDA Black Box warning for suicidality in individuals under age 25.

• Anxiety Disorders and Separation NuancesStranger anxiety is a normal developmental milestone that emerges between 8 to 10 months, peaking around 9 months of age.

  • Stranger anxiety is a normal developmental milestone that emerges between 8 to 10 months, peaking around 9 months of age.
  • Separation anxiety disorder requires at least 3 or more persistent symptoms lasting at least 4 weeks in children and adolescents, or 6 months or more in adults, with onset before 18 years of age (and can begin before 6 years of age).
  • Functional capacity is the core clinical metric that distinguishes separation anxiety disorder from age-appropriate developmental fears.
  • First-line treatment for separation anxiety disorder is psychotherapy (such as cognitive behavioral therapy, play therapy, or family behavioral therapy), not psychotropic medications.
  • SSRIs are not the first-line intervention for separation anxiety disorder in young children and should be reserved for severe or refractory cases.
  • Initial clinical evaluations for a child under 6 years of age with suspected separation anxiety should keep parents present to avoid overwhelming panic and allow observation of parent-child interactions.
• Key SignpostsPsychotherapy (cognitive behavioral therapy, play therapy, or family therapy) is the first-line treatment for separation anxiety disorder. Medications like SSRIs are second-line.

  • Psychotherapy (cognitive behavioral therapy, play therapy, or family therapy) is the first-line treatment for separation anxiety disorder. Medications like SSRIs are second-line.
  • Severe physical symptoms like crying fits leading to choking or vomiting when facing routine separation indicate profound functional distress. Do not dismiss these as normal developmental phases.
  • Forcing a young child under 6 years of age to be interviewed alone during an initial evaluation for separation anxiety. Separating the child from parents during the initial visit causes intense panic and invalidates the assessment.

  Board trap. Forcing a young child under 6 years of age to be interviewed alone during an initial evaluation for separation anxiety. Separating the child from parents during the initial visit causes intense panic and invalidates the assessment.

  Safety. Severe physical symptoms like crying fits leading to choking or vomiting when facing routine separation indicate profound functional distress. Do not dismiss these as normal developmental phases.

• Stranger anxiety typically occurs at approximately what age?D. 16 months old

  • D. 16 months old
• Trauma and the ACE FrameworkAn ACE score of 4 or higher exponentially increases lifetime risk for major depressive disorder, substance use disorders, suicide attempts, and chronic medical illness.

  • An ACE score of 4 or higher exponentially increases lifetime risk for major depressive disorder, substance use disorders, suicide attempts, and chronic medical illness.
  • Acute Stress Disorder is diagnosed when post-trauma symptoms last between 3 days and 1 month, whereas PTSD requires symptom persistence for greater than 1 month.
  • In children 6 years and younger, PTSD manifests through repetitive trauma play, frightening dreams without clear content, social withdrawal, and extreme temper outbursts.
  • First-line treatment for pediatric PTSD is Trauma-Focused Cognitive Behavioral Therapy (TF-CBT), not psychotropic medication.
  • SSRIs like fluoxetine (FDA approved for depression at age 8 and older) and escitalopram (FDA approved at age 12 and older) carry an FDA black box warning for increased suicidal ideation in youth under 25.
  • Suspected child physical or sexual abuse requires immediate mandatory reporting to state Child Protective Services (CPS) regardless of parental consent.
• Pediatric PTSD Diagnostic Criteria and TimelinesDuration: Symptoms must persist for more than 1 month. Symptoms lasting 3 days to 1 month represent Acute Stress Disorder.

  • Duration: Symptoms must persist for more than 1 month. Symptoms lasting 3 days to 1 month represent Acute Stress Disorder.
  • Intrusion: Intrusive memories, trauma-specific play reenactment, or distressing dreams. Young children often have nightmares without recognizable trauma content.
  • Avoidance: Persistent avoidance of distressing trauma memories, people, places, or conversations.
  • Cognition and Mood: Increased negative emotional states, diminished interest in play, detachment from peers, and inability to express positive emotions.
  • Arousal and Reactivity: Irritability, angry outbursts, hypervigilance, exaggerated startle response, concentration deficits, and sleep disturbance.
• Post-Traumatic Stress Disorder (PTSD)Think: persistent intrusive and hyperarousal symptoms lasting greater than 1 month

  • Think: persistent intrusive and hyperarousal symptoms lasting greater than 1 month
  • Priority: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
  • Boards are testing: symptom duration threshold of greater than 30 days and psychotherapy as primary care
• Acute Stress DisorderThink: severe post-trauma stress reactions lasting between 3 days and 1 month

  • Think: severe post-trauma stress reactions lasting between 3 days and 1 month
  • Priority: psychological first aid, supportive counseling, and safety stabilization
  • Boards are testing: recognizing symptoms under 1 month before diagnosing full PTSD
• Sleep Terrors vs PTSD Nightmares in ChildrenThink: sleep terrors occur in deep NREM sleep during early night with incomplete awakening and no dream recall

  • Think: sleep terrors occur in deep NREM sleep during early night with incomplete awakening and no dream recall
  • Priority: reassure parents that sleep terrors are benign and self-limiting in preschool children
  • Boards are testing: avoiding unnecessary abuse workups or trauma referrals for typical developmental parasomnias
• Sample Question: Methylphenidate and TicsFirst-line pharmacotherapy for ADHD in children aged 6 and older consists of methylphenidate or amphetamine formulations, while behavioral therapy is recommended for children under 5 years of age.

  • First-line pharmacotherapy for ADHD in children aged 6 and older consists of methylphenidate or amphetamine formulations, while behavioral therapy is recommended for children under 5 years of age.
  • Baseline and quarterly monitoring for children on stimulant therapy must include height, weight, blood pressure, and pulse.
  • Recognized potential adverse effects of methylphenidate include loss of appetite, weight loss, headache, insomnia, and exacerbation of tic disorders.
  • Hypersomnia is not an adverse effect of stimulant medications.
  • Approximately 20% of children with ADHD develop a chronic tic disorder independent of medication, while 50% of children with chronic tics or Tourette syndrome have comorbid ADHD.
  • Tics naturally wax and wane over time, so new or worsening tics may be coincidental or stimulant-induced.
• Pediatric Psychopharmacology for ADHDMethylphenidate and amphetamine compounds represent the gold standard first-line treatment for pediatric ADHD. Behavioral interventions are first-line for children under 5 years old.

  • Methylphenidate and amphetamine compounds represent the gold standard first-line treatment for pediatric ADHD. Behavioral interventions are first-line for children under 5 years old.
  • Central nervous system stimulants increase dopamine and norepinephrine signaling, which can elevate blood pressure, increase heart rate, suppress appetite, and trigger or worsen motor and vocal tics.
  • Baseline assessment prior to initiating stimulants requires checking cardiac history, vital signs, and growth parameters. Routine quarterly monitoring of height, weight, blood pressure, and pulse is mandatory.
  • Assuming every new tic during stimulant therapy is a permanent medication toxicity. Tics naturally wax and wane over time. However, if tics emerge or worsen significantly on methylphenidate, the board exam expects you to stop the stimulant and switch to atomoxetine.
  • Thinking type 2 diabetes is a contraindication to stimulant therapy. Stimulants do not directly alter glucose regulation and are safe to use in diabetic youth.

  Board trap. Assuming every new tic during stimulant therapy is a permanent medication toxicity. Tics naturally wax and wane over time. However, if tics emerge or worsen significantly on methylphenidate, the board exam expects you to stop the stimulant and switch to atomoxetine.

  Safety. Central nervous system stimulants increase dopamine and norepinephrine signaling, which can elevate blood pressure, increase heart rate, suppress appetite, and trigger or worsen motor and vocal tics.

• Managing Stimulant-Induced Tics vs Comorbid Tic DisordersEpidemiology: Up to 20% of children with ADHD experience chronic tics without any drug exposure. Conversely, 50% of youth with Tourette syndrome or chronic tics have comorbid ADHD.

  • Epidemiology: Up to 20% of children with ADHD experience chronic tics without any drug exposure. Conversely, 50% of youth with Tourette syndrome or chronic tics have comorbid ADHD.
  • Dosing rule: Avoid high doses of dextroamphetamine in children with motor or vocal tics.
• FDA Black Box Warning and Antidepressant SelectionFDA-Approved Antidepressants for Pediatric Depression: Fluoxetine is FDA approved for major depressive disorder in children aged 8 years and older, while escitalopram is FDA approved for adolescents aged 12 years and older.

  • FDA-Approved Antidepressants for Pediatric Depression: Fluoxetine is FDA approved for major depressive disorder in children aged 8 years and older, while escitalopram is FDA approved for adolescents aged 12 years and older.
  • FDA Black Box Warning: All antidepressant medications carry a black box warning for an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults up to age 24.
  • Clinical Monitoring Protocol: Close clinical monitoring for emergent suicidality, agitation, akathisia, or behavioral changes is required, particularly during the initial 1 to 2 months of treatment or following dose titrations.
  • Pediatric Dosing Dynamics: Children and adolescents do not automatically require lower antidepressant doses than adults because youth often possess faster hepatic clearance and metabolic rates, frequently requiring adult-level dosing to achieve therapeutic efficacy.
  • First-Line Treatment Approach: Evidence-based psychotherapy, such as cognitive behavioral therapy (CBT), or combination therapy (CBT plus an approved SSRI), is preferred over pharmacotherapy alone for pediatric depression.
  • Avoidance of Tricyclics: Tricyclic antidepressants (TCAs) are not indicated or recommended as second-line treatment in pediatric depression due to lack of demonstrated efficacy and high risk of lethal cardiotoxicity in overdose.
• Laboratory and Biological Safety PanelsHeight, weight, blood pressure, and pulse must be measured at baseline before initiating stimulant therapy for ADHD and monitored quarterly (every 3 months) to track growth suppression and cardiovascular safety.

  • Height, weight, blood pressure, and pulse must be measured at baseline before initiating stimulant therapy for ADHD and monitored quarterly (every 3 months) to track growth suppression and cardiovascular safety.
  • Fluoxetine (approved for ages 8 and older) and escitalopram (approved for ages 12 and older) are the only two FDA-approved SSRIs for major depressive disorder in children and adolescents.
  • All SSRIs carry an FDA Black Box Warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under age 25, requiring routine monitoring for depression and suicidality.
  • Non-stimulants such as atomoxetine or alpha-2 adrenergic agonists (guanfacine, clonidine) represent the preferred alternative when stimulants trigger motor tics or when active substance use disorders, severe hypertension, or structural cardiac defects are present.
  • Psychotherapy or family behavioral therapy is the first-line treatment for pediatric anxiety disorders, oppositional defiant disorder, and mild depressive presentations prior to initiating psychotropic medications.
• Pediatric Psychopharmacology and Safety ProtocolsFor ADHD in children aged 6 and older, stimulant medications (methylphenidate and amphetamine salts) remain the gold standard first-line treatment. In children under age 5, behavioral therapy is the recommended first-line intervention before starting psychotropics.

  • For ADHD in children aged 6 and older, stimulant medications (methylphenidate and amphetamine salts) remain the gold standard first-line treatment. In children under age 5, behavioral therapy is the recommended first-line intervention before starting psychotropics.
  • A common exam trap involves assuming children require lower weight-based antidepressant doses than adults. Because pediatric patients exhibit rapid hepatic metabolism and higher renal clearance, they frequently require adult-equivalent therapeutic doses of SSRIs.
  • For oppositional defiant disorder, separation anxiety disorder, and early behavioral disruptions, family behavioral therapy or psychotherapy is first-line over medication.

  Board trap. A common exam trap involves assuming children require lower weight-based antidepressant doses than adults. Because pediatric patients exhibit rapid hepatic metabolism and higher renal clearance, they frequently require adult-equivalent therapeutic doses of SSRIs.

  Safety. Prior to initiating stimulants, clinicians must obtain a complete personal and family cardiac history. Baseline measurements of height, weight, blood pressure, and pulse are required, followed by mandatory quarterly monitoring every 3 months to detect growth deceleration, hyperte

• Behavioral Activation and AIM Side EffectsOnly two SSRIs carry FDA approval for pediatric major depressive disorder: fluoxetine for children aged 8 and older, and escitalopram for adolescents aged 12 and older.

  • Only two SSRIs carry FDA approval for pediatric major depressive disorder: fluoxetine for children aged 8 and older, and escitalopram for adolescents aged 12 and older.
  • All antidepressants carry an FDA black box warning for an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under age 25.
  • Behavioral activation from SSRIs in pediatric patients presents as motor restlessness, agitation, impulsivity, insomnia, or disinhibition, which correlates directly with drug initiation or dose escalation rather than episodic bipolar cycling.
  • Baseline and quarterly physical monitoring for pediatric patients on stimulant pharmacotherapy requires measuring height, weight, blood pressure, and pulse to track growth suppression and cardiovascular changes.
  • Behavioral therapy is the recommended first-line intervention for ADHD in children under 5 years of age before considering stimulant pharmacotherapy.
  • Approximately 20% of children with ADHD develop a chronic tic disorder independently, and stimulants can unmask or worsen motor tics such as eye blinking or neck jerking.
• FDA Approvals and Black Box WarningFirst-line antidepressant pharmacotherapy for pediatric major depressive disorder is limited to two FDA-approved SSRIs: fluoxetine for patients aged 8 and older, and escitalopram for patients aged 12 and older.

  • First-line antidepressant pharmacotherapy for pediatric major depressive disorder is limited to two FDA-approved SSRIs: fluoxetine for patients aged 8 and older, and escitalopram for patients aged 12 and older.
  • Tricyclic antidepressants are not recommended as second-line therapy in children due to lack of pediatric efficacy and significant cardiotoxicity risks.
  • All antidepressants carry an FDA black box warning for increased suicidal ideation and suicidal behaviors in children, adolescents, and young adults up to age 25. Close clinical monitoring is essential during the initial weeks of treatment and after dose increases.

  Safety. All antidepressants carry an FDA black box warning for increased suicidal ideation and suicidal behaviors in children, adolescents, and young adults up to age 25. Close clinical monitoring is essential during the initial weeks of treatment and after dose increases.

• Behavioral Activation versus Bipolar ManiaBehavioral activation is a known adverse effect of SSRI therapy in pediatric populations, characterized by motor agitation, restlessness, impulsivity, insomnia, and behavioral disinhibition.

  • Behavioral activation is a known adverse effect of SSRI therapy in pediatric populations, characterized by motor agitation, restlessness, impulsivity, insomnia, and behavioral disinhibition.
  • Prepubertal onset of depression and a multigenerational family history of mood disorders elevate the risk of a child later transitioning from depression to bipolar disorder.

  Board trap. Do not confuse SSRI-induced behavioral activation with the onset of pediatric bipolar mania. Bipolar disorder is an episodic illness marked by distinct cycles of altered mood and grandiosity, whereas behavioral activation directly correlates with antidepressant initiation or dose

  Safety. Behavioral activation is a known adverse effect of SSRI therapy in pediatric populations, characterized by motor agitation, restlessness, impulsivity, insomnia, and behavioral disinhibition.

• Stimulant Side Effects and Physical MonitoringFirst-line pharmacological treatment for ADHD in children aged 6 and older includes stimulants such as methylphenidate or dextroamphetamine. For children under age 5, behavioral therapy is the recommended initial intervention.

  • First-line pharmacological treatment for ADHD in children aged 6 and older includes stimulants such as methylphenidate or dextroamphetamine. For children under age 5, behavioral therapy is the recommended initial intervention.
  • Required physical monitoring for pediatric patients taking stimulants includes baseline and quarterly measurements of height, weight, blood pressure, and pulse.
  • Common stimulant adverse effects include loss of appetite, weight loss, transient headaches, insomnia, and potential growth velocity suppression. Hypersomnia is not an adverse effect of stimulant therapy.

  Safety. Required physical monitoring for pediatric patients taking stimulants includes baseline and quarterly measurements of height, weight, blood pressure, and pulse.

• Movement Side Effects and Tic ManagementApproximately 20% of children with ADHD develop chronic tics, and 50% of children with Tourette syndrome have comorbid ADHD.

  • Approximately 20% of children with ADHD develop chronic tics, and 50% of children with Tourette syndrome have comorbid ADHD.
  • When a child on a methylphenidate or dextroamphetamine stimulant develops new motor tics such as eye blinking or neck jerking, do not increase the stimulant dose or switch to another stimulant formulation.
  • First-line adjustment for stimulant-induced or exacerbated motor tics is switching to a non-stimulant medication such as atomoxetine or an alpha-2 adrenergic agonist.

  Board trap. When a child on a methylphenidate or dextroamphetamine stimulant develops new motor tics such as eye blinking or neck jerking, do not increase the stimulant dose or switch to another stimulant formulation.

• Sample Question: 32-month-old DevelopmentBabbling begins between 5 and 7 months of age.

  • Babbling begins between 5 and 7 months of age.
  • Sitting alone for 30 seconds occurs between 6 and 8 months of age.
  • Stranger anxiety typically emerges between 8 and 10 months of age.
  • Saying specific words like mama or dada occurs between 10 and 12 months of age.
  • Walking solo occurs between 12 and 18 months of age.
  • Kicking a ball using large muscle groups occurs between 18 and 30 months of age.
• Table 15-1: Developmental Milestone InventoryParental education and reassurance is the first-line intervention when a caregiver expresses concern over normal developmental behaviors like parallel play or imaginary friends.

  • Language milestones progress sequentially across infancy and early childhood.
  • Babbling opens language development between 5 and 7 months.
  • Specific words like mama or dada emerge between 10 and 12 months.
  • Two-word sentences develop between 2 and 3 years.

  Board trap. Do not confuse normal parallel play in toddlers under 3 years of age with social detachment or autism spectrum disorder. Exam stems use parental anxiety to tempt test-takers into ordering unnecessary referrals or diagnostic workups.

  Safety. Any clear loss or regression of previously mastered developmental milestones is an emergency signal that requires immediate comprehensive developmental and neurological evaluation.

• Sample Question: Kitana and Parental ConsentFluoxetine is FDA approved for major depressive disorder in pediatric patients down to age 8, while escitalopram is approved down to age 12.

  • Fluoxetine is FDA approved for major depressive disorder in pediatric patients down to age 8, while escitalopram is approved down to age 12.
  • General psychiatric treatment of a minor requires parental or guardian consent, whereas state exceptions allow minors to consent independently for family planning, reproductive care, STI testing, and substance use treatment.
  • Non-suicidal self-injury, such as superficial cutting without suicidal intent, does not legally mandate parental disclosure if reporting would destroy therapeutic trust and there is no active safety threat.
  • Confidentiality must be broken immediately when an adolescent expresses active suicidal ideation with intent, homicidal ideation, or ongoing physical or sexual abuse.
  • The HEADSS mnemonic structures adolescent psychosocial screening across Home, Education, Activities, Drugs, Sex, and Suicidality.
  • Tricyclic antidepressants are contraindicated as second-line treatment for pediatric depression due to cardiotoxicity and lethal overdose risk.
• Adolescent Confidentiality and Parental Consent FrameworkFor mild to moderate pediatric depression, psychotherapy such as cognitive behavioral therapy is first-line treatment. When medication is required, fluoxetine or escitalopram are first-line agents.

  • For mild to moderate pediatric depression, psychotherapy such as cognitive behavioral therapy is first-line treatment. When medication is required, fluoxetine or escitalopram are first-line agents.
  • Breach confidentiality and notify parents or emergency authorities immediately if an adolescent reveals active suicidal intent, a concrete suicide plan, homicidal ideation, or active child abuse.

  Board trap. Do not confuse general psychiatric care with protected minor healthcare services. Parental consent is legally required before initiating routine psychiatric treatment or psychotropic medications in minors. However, most states permit adolescents to consent independently for subst

  Safety. Breach confidentiality and notify parents or emergency authorities immediately if an adolescent reveals active suicidal intent, a concrete suicide plan, homicidal ideation, or active child abuse.

• Psychosocial Screening via the HEADSS ToolH: Home environment, family stability, and living arrangements.

  • H: Home environment, family stability, and living arrangements.
  • E: Education, school performance, attendance, and employment plans.
  • A: Activities, peer relationships, hobbies, and screen time.
  • D: Drugs, alcohol, tobacco, and vaping habits.
  • S: Sex, sexuality, contraception, and gender identity.
  • S: Suicidality, self-harm, mood, and overall mental health.
• Academic Accommodations and AdvocacyPMHNP Advocacy Role: The PMHNP advocates by documenting specific functional deficits and recommending targeted classroom modifications, such as preferential seating, extended testing time, and movement breaks.

  • PMHNP Advocacy Role: The PMHNP advocates by documenting specific functional deficits and recommending targeted classroom modifications, such as preferential seating, extended testing time, and movement breaks.
  • Parental Consent Rules: General psychiatric treatment of a minor requires parental consent, but adolescents can independently access substance use treatment, family planning, and STI services without parental consent in most states.
  • Adolescent Confidentiality: Parents do not have an unconditional right to know all psychotherapy session details, but active suicidal ideation, homicidal threat, or child abuse requires an immediate breach of confidentiality.
  • Non-Suicidal Self-Injury: Superficial cutting without suicidal intent or an active plan does not legally force an immediate breach of confidentiality, allowing the clinician to work collaboratively on safety.
  • Pediatric Depression FDA Approvals: Only two SSRIs are FDA approved for pediatric depression: fluoxetine for ages 8 and older, and escitalopram for ages 12 and older.
  • High-Risk Youth Screening: Adolescents presenting with sexual orientation confusion, substance use, or behavioral disruption require immediate and routine screening for major depressive disorder and suicidality.
• Legal Frameworks for Educational SupportIndividuals with Disabilities Education Act (IDEA): Governs the Individualized Education Program (IEP). It applies to children whose disability adversely impacts educational performance and requires specialized instruction.

  • Individuals with Disabilities Education Act (IDEA): Governs the Individualized Education Program (IEP). It applies to children whose disability adversely impacts educational performance and requires specialized instruction.
  • Section 504 of the Rehabilitation Act of 1973: Covers students with a physical or mental impairment that substantially limits one or more major life activities. It provides accommodations in the general education setting without requiring special education coursework.
  • PMHNP Clinical Advocacy: The NP performs diagnostic evaluation, outlines specific cognitive or emotional limitations, and submits formal documentation to school multidisciplinary teams to secure needed services.
• Classroom Accommodation StrategiesEnvironmental Modifications: Preferential seating near the instructor, reduction of extraneous environmental stimuli, and placement away from distracting windows or doors.

  • Environmental Modifications: Preferential seating near the instructor, reduction of extraneous environmental stimuli, and placement away from distracting windows or doors.
  • Instructional Adjustments: Breaking complex multi-step assignments into discrete steps, providing written and visual outlines, and allowing extra time for examinations.
  • Behavioral and Somatic Support: Scheduled movement breaks for children with ADHD, access to a designated quiet space during acute anxiety, and a modified homework load to prevent cognitive fatigue.
• Parental Consent and Adolescent Privacy LimitsConsent vs Assent: Legally, parents or legal guardians provide informed consent for minors under age 18. Minors provide developmental assent by agreeing to the treatment plan.

  • Consent vs Assent: Legally, parents or legal guardians provide informed consent for minors under age 18. Minors provide developmental assent by agreeing to the treatment plan.
  • Confidentiality Scope: Establishing clear privacy limits during the initial visit engages the youth. Parents do not receive verbatim reports of therapy sessions unless safety is compromised.
  • Statutory Exemptions: In most jurisdictions, adolescents may independently consent to substance use disorder treatment, reproductive health services, and emergency crisis stabilization without parental notification.
• Youth Suicide Safety and Risk AssessmentHEADS Psychosocial Assessment: Evaluates Home, Education/employment, Activities, Drugs/alcohol, Sexuality, and Suicidality/mental health.

  • HEADS Psychosocial Assessment: Evaluates Home, Education/employment, Activities, Drugs/alcohol, Sexuality, and Suicidality/mental health.
  • Breaching Confidentiality: Active suicidal intent, explicit plan, access to lethal means, homicidal threats, or suspected child abuse legally mandates parental notification and safety planning.
  • Non-Suicidal Self-Injury: Differentiated from suicidal behavior. Superficial cutting without suicidal intent warrants clinical processing, coping skills training, and voluntary family inclusion rather than an immediate punitive confidentiality breach.
  • FDA-Approved Pharmacotherapy: For youth with major depressive disorder, fluoxetine is approved for ages 8 and older, and escitalopram is approved for ages 12 and older.
• Signposted Core ConceptsPsychotherapy, such as Cognitive Behavioral Therapy or family behavioral therapy, is the first-line intervention for mild to moderate pediatric mood, anxiety, and oppositional behaviors before initiating psychotropics.

  • Psychotherapy, such as Cognitive Behavioral Therapy or family behavioral therapy, is the first-line intervention for mild to moderate pediatric mood, anxiety, and oppositional behaviors before initiating psychotropics.
  • Immediate safety risks, including active suicidal ideation with a plan or access to firearms, require breaking confidentiality, notifying parents, and establishing a restrictive safety environment.
  • Assuming that parents have an absolute legal right to read all psychotherapy notes or know every disclosed secret. Parental consent is required for general treatment, but confidentiality protects the therapeutic alliance unless an acute safety threat occurs.

  Board trap. Assuming that parents have an absolute legal right to read all psychotherapy notes or know every disclosed secret. Parental consent is required for general treatment, but confidentiality protects the therapeutic alliance unless an acute safety threat occurs.

  Safety. Immediate safety risks, including active suicidal ideation with a plan or access to firearms, require breaking confidentiality, notifying parents, and establishing a restrictive safety environment.

• Substance Use Screening: CRAFFT ToolCRAFFT Screening Threshold: A score of 2 or more positive "Yes" answers on the CRAFFT tool indicates a high likelihood of an adolescent substance use disorder and mandates full clinical assessment.

  • CRAFFT Screening Threshold: A score of 2 or more positive "Yes" answers on the CRAFFT tool indicates a high likelihood of an adolescent substance use disorder and mandates full clinical assessment.
  • CRAFFT Mnemonic Components: Evaluates riding in a Car driven by someone high or drinking, using to Relax, using Alone, Forgetting events while using, Friends or family telling you to cut down, and getting into Trouble while using.
  • Adolescent Minor Consent Protections: Most state laws allow adolescents to independently consent to substance use disorder treatment and family planning services without parental consent or notification.
  • Parental Consent Requirement: Parental or legal guardian consent is required prior to initiating primary psychiatric treatment for a minor in most jurisdictions.
  • Confidentiality Limits: Confidentiality must be broken to notify parents or authorities only when an adolescent poses an imminent safety threat to self or others, including active suicidal ideation with intent.
  • Non-Suicidal Self-Injury Protocol: Providers are not legally required to report non-suicidal self-harm behaviors, such as superficial cutting without suicidal intent, to parents if doing so harms the therapeutic relationship.
• Substance Use Screening: The CRAFFT ToolC - Car: Have you ever ridden in a car driven by someone, including yourself, who was high or had been using alcohol or drugs?

  • C - Car: Have you ever ridden in a car driven by someone, including yourself, who was high or had been using alcohol or drugs?
  • R - Relax: Do you ever use alcohol or drugs to relax, feel better about yourself, or fit in?
  • A - Alone: Do you ever use alcohol or drugs while you are by yourself or alone?
  • F - Forget: Do you ever forget things you did while using alcohol or drugs?
  • F - Friends: Do your family or friends ever tell you that you should cut down on your drinking or drug use?
  • T - Trouble: Have you ever gotten into trouble while you were using alcohol or drugs?

  Board trap. Do not confuse the CRAFFT scoring threshold with adult screening tools. Answering "Yes" to 2 or more items is a positive screen that indicates significant risk and necessitates a comprehensive chemical dependency evaluation.

• Adolescent Development, Consent, and ConfidentialityEstablish clear boundaries of confidentiality at the very beginning of the clinical relationship with both the adolescent and parents present.

  • Establish clear boundaries of confidentiality at the very beginning of the clinical relationship with both the adolescent and parents present.
  • Protected minor services: Adolescents may access family planning, contraception, sexually transmitted infection testing, and substance use disorder treatment without parental consent or notification in most states.
  • Psychiatric consent rules: Initiating psychotropic medications or formal psychiatric treatment requires parental or legal guardian consent, along with the minor's assent when age-appropriate.
  • Therapy privacy: Parents do not have an automatic right to review session notes or obtain detailed accounts of private psychotherapy discussions.
• Youth Suicide Safety and Mandatory ReportingRoutinely screen for depression and suicidality at every visit for adolescents presenting with substance use, behavioral changes, or psychosocial stressors.

  • Confidentiality must be breached immediately if an adolescent discloses active suicidal ideation with plan or intent, homicidal intent, or if child abuse or neglect is suspected. Mandatory child abuse reporting to state Child Protective Services is legally required.
  • High-risk populations: Sexual minority youth, adolescents experiencing sexual orientation confusion, and youth with co-occurring substance use disorders face significantly elevated rates of depression and suicide.
  • Routinely screen for depression and suicidality at every visit for adolescents presenting with substance use, behavioral changes, or psychosocial stressors.

  Safety. Confidentiality must be breached immediately if an adolescent discloses active suicidal ideation with plan or intent, homicidal intent, or if child abuse or neglect is suspected. Mandatory child abuse reporting to state Child Protective Services is legally required.

• Which statement is FALSE regarding parental consentWhy It Is Correct

  • Why It Is Correct
  • Why the Other Choices Are Wrong
  • A: This is a true statement; minors can legally receive family planning and reproductive health services without parental consent.
  • C: This is a true statement; most state laws grant minors the legal authority to seek substance use disorder treatment independently.
  • D: This is a true statement; non-suicidal self-injury like superficial cutting without suicidal intent does not legally force a provider to inform parents if doing so harms patient safety or alliance.
  • Test-Taking Pearl
• Right to know what teenager reports during psychotherapyWhy It Is Correct

  • Why It Is Correct
  • Why the Other Choices Are Wrong
  • A: True is incorrect because forcing disclosure of routine psychotherapy discussions destroys trust and violates established adolescent healthcare confidentiality standards.
  • Test-Taking Pearl
  • Concept Tested: Adolescent psychotherapy privacy boundaries.